Blog
RSS FeedPosted by Michael Wonder on 10 Dec 2019
Pharmacare with no new medicines
10 December 2019 - Meeting with pricing officials shows that government's true goal is to slash prices so low that no ...
Posted by Michael Wonder on 07 Dec 2019
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance for Skyrizi (risankizumab) for the treatment of moderate to severe plaque psoriasis
6 December 2019 - In May 2019 , Skyrizi received positive reimbursement recommendations from the Canadian Agency for Drugs and Technologies ...
Posted by Michael Wonder on 28 Nov 2019
Takhzyro (lanadelumab injection) receives positive recommendation from CADTH's Canadian Drug Expert Committee for the routine prevention of hereditary angioedema attacks
22 November 2019 - The positive recommendation is supported by the recently released findings of the Phase 3 Help Study™ Open-Label ...
Posted by Michael Wonder on 25 Nov 2019
Proposed Ontario drug regulation changes worry policy experts
22 November 2019 - The Ontario government is proposing drug regulation changes that it says will remove red tape and ...
Posted by Michael Wonder on 23 Nov 2019
Santen receives CADTH Canadian Drug Expert Committee reimbursement recommendation for Verkazia (cyclosporin 0.1%) eye drops
22 November 2019 - Santen Canada announced that the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee ...
Posted by Michael Wonder on 18 Nov 2019
Ontario and Quebec provide reimbursement for HIV therapies Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)
18 November 2019 - For more than 30 years, Merck has been committed to scientific research and discovery in HIV that ...
Posted by Michael Wonder on 18 Nov 2019
Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in health technology assessment in Canada
15 November 2019 - Consideration of ethical, legal, and social issues plus patient values (ELSI+) in health technology assessment is challenging ...
Posted by Michael Wonder on 18 Nov 2019
'This drug saved my life;' cystic fibrosis patient accuses drug company, Canada of stalling on approval
17 November 2019 - A West Island woman living with cystic fibrosis says the prohibitive price of a drug is ...
Posted by Michael Wonder on 29 Oct 2019
Costly prescription eye treatment highlights a loophole in Canada’s drug-price regulation process
28 October 2019 - The Ontario government has begun covering $100,000-a-year eye drops for an ultrarare disease, bringing relief to ...
Posted by Michael Wonder on 28 Oct 2019
It’s time for Canada to embrace universal pharmacare and protect drug coverage from corporate erosion
28 October 2019 - President Trump recently unveiled an executive order — originally titled “Protecting Medicare from Socialist Destruction” — ...
Posted by Michael Wonder on 23 Oct 2019
Patients in Quebec now have access to Dupixent for the treatment of moderate-to-severe atopic dermatitis
22 October 2019 - Quebec becomes the first province to list Dupixent for public reimbursement in adult patients. ...
Posted by Michael Wonder on 21 Oct 2019
Voters beware: national pharmacare is unnecessary, bad for privately insured Canadians and costly for taxpayers
18 October 2019 - Research has shown it would be less disruptive and less expensive to just fill the gaps caused ...
Posted by Michael Wonder on 16 Oct 2019
Election 2019: unprecedented hope for universal pharmacare
15 October 2019 - Pharmacare continues to be the most salient unfinished business of Canada’s public health care system since Medicare ...
Posted by Michael Wonder on 09 Oct 2019
Low-income Canadians struggling to pay for medications plead for pharmacare
8 October 2019 - Three of the major federal parties have promised they’ll introduce universal pharmacare if elected. ...
Posted by Michael Wonder on 03 Oct 2019
Dr. Brian O’Rourke to retire as CADTH’s President and CEO
3 October 2019 - Dr. Brian O’Rourke has announced his intention to retire from CADTH, effective 31 March 2020. ...